ClinicalTrials.gg
CompletedNCT01370902Updated Dec 23, 2014

Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

A Phase 1 interventional study of NNC 0141-0000-0100 and placebo in Inflammation and Rheumatoid Arthritis, sponsored by Innate Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-12-23.

Primary conditionArthritis, RheumatoidRegistry: InflammationReclassifiedWhy we changed it
Registry
Inflammation — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Rheumatoid
Why
  1. Inflammation is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Arthritis, Rheumatoid.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Innate Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 361 studies in Arthritis, Rheumatoid with a site in Germany — 26 open to participants now, 49 under way, 3 of them phase 3. Arthritis, Rheumatoid · Germany.

Enrollment
224th of 296
92 · median 262
Started
2011
with 20 others
Phase 1
34 of 361
6 open now
Registered
132nd of 361
by date

Among the 361 studies in Arthritis, Rheumatoid with a site in Germany, this one is the 224th largest by enrollment of the 296 interventional ones that give a count, is one of 21 that started in 2011, is one of 34 in phase 1, and was the 132nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

26 of the 361 studies in Arthritis, Rheumatoid with a site in Germany are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 361 studies in Arthritis, Rheumatoid with a site in Germany, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this dose-escalating trial is to assess the safety, tolerability, pharmacokinetics (the rate at which the body eliminates the trial drug) and pharmacodynamics (the effect of the investigated drug on the body) of single and repeated doses of NNC141-0100 in subjects with Rheumatoid Arthritis.

03

Conditions studied

  • Inflammation
  • Rheumatoid Arthritis

Browse trials for

04

In context

Arthritis, Rheumatoid Reclassified

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

This study's enrollment of 92 is close to the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.

Browse Arthritis, Rheumatoid studies →

Lead sponsor

Innate Pharma is the lead sponsor of 17 studies on the registry; 1 is open to participants now.

Compared within Arthritis, Rheumatoid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammation. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • A diagnosis of rheumatoid arthritis (RA) according to the American College of Rheumatology (ACR1987 classification) of at least 3 months duration prior to randomisation
  • Active Rheumatoid Arthritis (RA) characterised by a DAS28-CRP (Disease Activity Score of 28 joints, calculated with CRP (C-reactive protein) value) greater than or equal to 3.2
  • Females must be or surgically sterile (post-menopausal for at least 1 year) or be willing to use highly effective method of
  • Males must be willing to use highly effective contraception
  • Subjects on stable doses of methotrexate (7.5 to 25 mg/week, both inclusive) for at least 4 weeks prior to randomisation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Single-dose (SD) trial part (i.v.)

    Drug: NNC 0141-0000-0100 · Drug: placebo

  • Experimental
    Single-dose (SD) trial part (s.c.)

    Drug: NNC 0141-0000-0100 · Drug: placebo

  • Experimental
    Multiple-dose (MD) trial part (s.c.)

    Drug: NNC 0141-0000-0100 · Drug: placebo

Interventions

  • Single dose administered subcutaneously (under the skin), up to six dose levels. Progression to next dose will be based on safety evaluation. Initiation of the MD s.c. phase will depend on the results from the SD i.v. cohorts as well as the first two dose cohorts of the SD s.c. part

  • Drugplacebo

    Single dose administered subcutaneously (under the skin) as a comparator at all dose levels

  • Multiple doses administered subcutaneously (under the skin) at 4 different occasions with a dosing interval of two weeks, at five different dose levels.

  • Drugplacebo

    Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels

  • Single dose administered intravenously (into a vein), up to nine dose levels. Progression to next dose will be based on safety evaluation. Initiation of the SD s.c. phase will depend on the results from the first three dose cohorts of the SD i.v. part

  • Drugplacebo

    Single dose administered intravenously (into a vein), as a comparator at all dose levels

07

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Time frame: from trial product administration to week 12

Secondary outcomes

  1. Antibodies against NNC141-0100

    Time frame: from trial product administration until final visit (week 12 or longer if applicable)

  2. Area under the serum concentration-time curve - SD trial part

    Time frame: from trial product administration until final visit (week 12 or longer if applicable)

  3. Terminal half-life (t½) - SD trial part

    Time frame: from trial product administration until final visit (week 12 or longer if applicable)

  4. Terminal half-life (t½) - MD trial part

    Time frame: from trial product administration until final visit (week 12 or longer if applicable)

08

Study locations

1 site
  • Berlin, 13353, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2011
First posted
Jun 10, 2011
Start
May 2011
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Last update
Dec 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01370902
Lead sponsor
Innate Pharma
Responsible party
Sponsor
First posted
Jun 10, 2011
Start date
May 2011
Primary completion
Mar 2014
Completion
Mar 2014
Last update
Dec 23, 2014

Study contacts

Renaud Buffet
study director · Innate Pharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Monalizumab

Start the discussion